gms | German Medical Science

23rd Annual Meeting of the German Retina Society

German Retina Society

24.09. - 25.09.2010, Freiburg

Local tumour control and enucleation rate after 106Ru-Brachytherapy for Uveal Melanoma

Meeting Abstract

  • Nona Lakotka - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Benjamin Franklin, Berlin
  • L. Alekian - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Benjamin Franklin, Berlin
  • G. Willerding - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Benjamin Franklin, Berlin
  • L. Krause - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Benjamin Franklin, Berlin
  • J. Wachtlin - Eye Clinic Sankt Gertrauden-Hospital, Berlin
  • M. H. Foerster - Charité, University School of Medicine Berlin, University Eye Clinic, Campus Benjamin Franklin, Berlin
  • N. E. Bechrakis - University Eye Clinic, Innsbruck

German Retina Society. 23rd Annual Conference of the German Retina Society. Freiburg i. Br., 24.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10rg31

doi: 10.3205/10rg31, urn:nbn:de:0183-10rg311

This is the English version of the article.
The German version can be found at: http://www.egms.de/de/meetings/rg2010/10rg31.shtml

Published: September 21, 2010

© 2010 Lakotka et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Purpose: To analyse local tumour control, radiation related complications and enucleation rate after 106Ru-brachytherapy of uveal melanoma.

Methods: A retrospective study was performed. 948 eyes with choroidal or ciliary body melanomas were treated with 106Ruthenium episcleral plaques from October 1992 through December 2005. The Kaplan-Meier method and Cox-Regression model were used for statistical analysis.

Results: The mean follow-up was 4.1 years (0.09-14.1 years). The mean tumour size was 5.1 mm ± 2.1 mm (min: 1.0 mm; max: 12.3 mm) at the time of treatment. The mean tumour base was 11.7 mm ±3.0 mm (min 2.7 mm, max 23.4 mm). 17.7% of eyes showed evidence of ciliary body infiltration and 3.9% had infiltration of the iris. 3.5% of eyes had extraocular growth. The local tumour control rates were 91.3% and 89.7% at 5 and 10 years, respectively. The mean time of appearance of tumour recurrences was 2 years ± 1.6 year (min 4 months; max 7.9 years.). The eye-preservation was 95.0% and 93.7% at 5 and 10 years, respectively. The reason for secondary enucleation was tumour recurrence in 66.7% and radiation-related complications in 33.3%.

Conclusions: 106Ru-Brachytherapy in the treatment of uveal melanoma is an effective method with a favourable local tumour control and eye preservation rate. The Life-long monitoring for recurrences is warranted.